Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 220.37% | 18.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 68.59% | 18.33% | |||
| Operating Income | -68.59% | -18.33% | |||
| Income Before Tax | -72.62% | -27.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -72.62% | -27.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -72.62% | -27.14% | |||
| EBIT | -68.59% | -18.33% | |||
| EBITDA | -68.67% | -18.37% | |||
| EPS Basic | -61.91% | 27.30% | |||
| Normalized Basic EPS | -61.85% | 27.27% | |||
| EPS Diluted | -61.91% | 27.30% | |||
| Normalized Diluted EPS | -61.85% | 27.27% | |||
| Average Basic Shares Outstanding | 6.63% | 74.85% | |||
| Average Diluted Shares Outstanding | 6.63% | 74.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||